Experienced in Scleroderma

Jieruo R. Gu

600 Tianhe Road, 
Guangzhou, CN 
Experienced in Scleroderma
600 Tianhe Road, 
Guangzhou, CN 
OverviewLocationsClinical Research

Overview

Jieruo Gu practices in Guangzhou, China. Gu is rated as an Experienced expert by MediFind in the treatment of Scleroderma. Their top areas of expertise are Ankylosing Spondylitis, Arthritis, Axial Spondyloarthritis (AxSpA), and Systemic Lupus Erythematosus (SLE).

Their clinical research consists of co-authoring 154 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Scleroderma.

Locations

600 Tianhe Road, Guangzhou, 510630, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Multicenter, Randomized, Double-Blind and Placebo-Controlled 16-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Chinese Patients With Radiographic Axial Spondyloarthritis
A Multicenter, Randomized, Double-Blind and Placebo-Controlled 16-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Chinese Patients With Radiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: April 14, 2023
Intervention Type: Drug
Study Drug: Ixekizumab
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
View 1 Less Clinical Trial

154 Total Publications

CD14+CD11c+HLA-II- monocytes are identified to be associated with osteoclastogenesis in ankylosing spondylitis.
CD14+CD11c+HLA-II- monocytes are identified to be associated with osteoclastogenesis in ankylosing spondylitis.
Journal: Clinical immunology (Orlando, Fla.)
Published: June 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Gu's expertise for a condition
ConditionClose
    View All 24 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile